Role of Epidermal Growth Factor Receptor Inhibitors in Epidermal Growth Factor Receptor Wild-Type Non-Small-Cell Lung Cancer

被引：79

作者：

Laurie, Scott A. ^{[1
]}

Goss, Glenwood D. ^{[1
]}

机构：

[1] Univ Ottawa, Ottawa Hosp Canc Ctr, Ottawa, ON K1H 8L6, Canada

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2013年 / 31卷 / 08期

关键词：

RANDOMIZED PHASE-II; PREVIOUSLY TREATED PATIENTS; 1ST-LINE TAXANE/CARBOPLATIN; MOLECULAR PREDICTORS; ELDERLY-PATIENTS; SUPPORTIVE CARE; ERBB RECEPTORS; GEFITINIB PLUS; ERLOTINIB; CHEMOTHERAPY;

D O I：

10.1200/JCO.2012.43.4522

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Worldwide, the majority of patients with advanced non-small-cell lung cancer (NSCLC) do not have activating mutations in the tyrosine kinase domain of the epidermal growth factor receptor (EGFR). These wild-type patients comprise a significant proportion of those treated with inhibitors of this pathway, and data from randomized trials suggest that some of these wild-type patients will derive a modest benefit from these agents. Although the detection of an activating mutation predicts for a greater likelihood of response and longer progression-free survival from an EGFR tyrosine kinase inhibitor, currently there are no biomarkers that consistently and reproducibly predict for lack of benefit in wild-type patients. Several strategies to increase the efficacy of these inhibitors in wild-type NSCLC are the subject of ongoing investigations. J Clin Oncol 31:1061-1069. (C) 2013 by American Society of Clinical Oncology

引用

页码：1061 / 1069

页数：9

共 67 条

[21] Randomized Phase II Study of Gefitinib Compared With Placebo in Chemotherapy-Naive Patients With Advanced Non-Small-Cell Lung Cancer and Poor Performance Status [J].

Goss, Glenwood ;

Ferry, David ;

Wierzbicki, Rafal ;

Laurie, Scott A. ;

Thompson, Joyce ;

Biesma, Bonne ;

Hirsch, Fred R. ;

Varella-Garcia, Marileila ;

Duffield, Emma ;

Ataman, Ozlem U. ;

Zarenda, Marc ;

Armour, Alison A. .

JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (13) :2253-2260

[22] International multicenter randomized phase III study of first-line erlotinib (E) followed by second-line cisplatin plus gemcitabine (CG) versus first-line CG followed by second-line E in advanced non-small cell lung cancer (aNSCLC): The TORCH trial [J].

Gridelli, C. ;

Ciardiello, F. ;

Feld, R. ;

Butts, C. A. ;

Gebbia, V. ;

Genestreti, G. ;

Favaretto, A. G. ;

Wierzbicki, R. ;

Gallo, C. ;

Perrone, F. .

JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)

[23] First-SIGNAL: First-Line Single-Agent Iressa Versus Gemcitabine and Cisplatin Trial in Never-Smokers With Adenocarcinoma of the Lung [J].

Han, Ji-Youn ;

Park, Keunchil ;

Kim, Sang-We ;

Lee, Dae Ho ;

Kim, Hyae Young ;

Kim, Heung Tae ;

Ahn, Myung Ju ;

Yun, Tak ;

Ahn, Jin Seok ;

Suh, Cheolwon ;

Lee, Jung-Shin ;

Yoon, Sung Jin ;

Han, Jong Hee ;

Lee, Jae Won ;

Jo, Sook Jung ;

Lee, Jin Soo .

JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (10) :1122-1128

[24] A Randomized Phase II Study of Gefitinib Plus Simvastatin Versus Gefitinib Alone in Previously Treated Patients with Advanced Non-Small Cell Lung Cancer [J].

Han, Ji-Youn ;

Lee, Soo-Hyun ;

Yoo, Nam Jin ;

Lee, Suk Hyung ;

Moon, Yoon Joo ;

Yun, Tak ;

Kim, Heung Tae ;

Lee, Jin Soo .

CLINICAL CANCER RESEARCH, 2011, 17 (06) :1553-1560

[25] Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy [J].

Hanna, N ;

Shepherd, FA ;

Fossella, FV ;

Pereira, JR ;

De Marinis, F ;

von Pawel, J ;

Gatzemeier, U ;

Tsao, TCY ;

Pless, M ;

Muller, T ;

Lim, HL ;

Desch, C ;

Szondy, K ;

Gervais, R ;

Shaharyar ;

Manegold, C ;

Paul, S ;

Paoletti, P ;

Einhorn, L ;

Bunn, PA .

JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (09) :1589-1597

[26] Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: A phase III trial - INTACT 2 [J].

Herbst, RS ;

Giaccone, G ;

Schiller, JH ;

Natale, RB ;

Miller, V .

JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (05) :785-794

[27] TRIBUTE: A phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer [J].

Herbst, RS ;

Prager, D ;

Hermann, R ;

Fehrenbacher, L ;

Johnson, BE ;

Sandler, A ;

Kris, MG ;

Tran, HT ;

Klein, P ;

Li, X ;

Ramies, D ;

Johnson, DH ;

Miller, VA .

JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (25) :5892-5899

[28] Molecular predictors of outcome with gefitinib in a phase III placebo-controlled study in advanced non-small-cell lung cancer [J].

Hirsch, Fred R. ;

Varella-Garcia, Marileila ;

Bunn, Paul A., Jr. ;

Franklin, Wilbur A. ;

Dziadziuszko, Rafal ;

Thatcher, Nick ;

Chang, Alex ;

Parikh, Purvish ;

Rodrigues Pereira, Jose ;

Ciuleanu, Tudor ;

von Pawel, Joachim ;

Watkins, Claire ;

Flannery, Angela ;

Ellison, Gillian ;

Donald, Emma ;

Knight, Lucy ;

Parums, Dinah ;

Botwood, Nicholas ;

Holloway, Brian .

JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (31) :5034-5042

[29] ERBB receptors and cancer: The complexity of targeted inhibitors [J].

Hynes, NE ;

Lane, HA .

NATURE REVIEWS CANCER, 2005, 5 (05) :341-354

[30] Analysis of Potential Predictive Markers of Cetuximab Benefit in BMS099, a Phase III Study of Cetuximab and First-Line Taxane/Carboplatin in Advanced Non-Small-Cell Lung Cancer [J].

Khambata-Ford, Shirin ;

Harbison, Christopher T. ;

Hart, Lowell L. ;

Awad, Melissa ;

Xu, Li-An ;

Horak, Christine E. ;

Dakhil, Shaker ;

Hermann, Robert C. ;

Lynch, Thomas J. ;

Weber, Martin R. .

JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (06) :918-927

← 1 2 3 4 5 6 7 →